175 related articles for article (PubMed ID: 23856527)
21. Photomodulation of G protein-coupled adenosine receptors by a novel light-switchable ligand.
Bahamonde MI; Taura J; Paoletta S; Gakh AA; Chakraborty S; Hernando J; Fernández-Dueñas V; Jacobson KA; Gorostiza P; Ciruela F
Bioconjug Chem; 2014 Oct; 25(10):1847-54. PubMed ID: 25248077
[TBL] [Abstract][Full Text] [Related]
22. Adenosine A
Yu F; Zhu C; Xie Q; Wang Y
J Med Chem; 2020 Nov; 63(21):12196-12212. PubMed ID: 32667814
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-n-methyluronamide in human leukemia cells.
Mlejnek P; Dolezel P; Kosztyu P
J Cell Physiol; 2012 Feb; 227(2):676-85. PubMed ID: 21520073
[TBL] [Abstract][Full Text] [Related]
24. Structural Characterization of Agonist Binding to an A
Stamatis D; Lagarias P; Barkan K; Vrontaki E; Ladds G; Kolocouris A
J Med Chem; 2019 Oct; 62(19):8831-8846. PubMed ID: 31502843
[TBL] [Abstract][Full Text] [Related]
25. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.
Young A; Ngiow SF; Barkauskas DS; Sult E; Hay C; Blake SJ; Huang Q; Liu J; Takeda K; Teng MWL; Sachsenmeier K; Smyth MJ
Cancer Cell; 2016 Sep; 30(3):391-403. PubMed ID: 27622332
[TBL] [Abstract][Full Text] [Related]
26. The stimulation of A(3) adenosine receptors reduces bone-residing breast cancer in a rat preclinical model.
Varani K; Vincenzi F; Targa M; Paradiso B; Parrilli A; Fini M; Lanza G; Borea PA
Eur J Cancer; 2013 Jan; 49(2):482-91. PubMed ID: 22770890
[TBL] [Abstract][Full Text] [Related]
27. CD73-adenosine: a next-generation target in immuno-oncology.
Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
[TBL] [Abstract][Full Text] [Related]
28. Decreased behavioral activation following caffeine, amphetamine and darkness in A3 adenosine receptor knock-out mice.
Björklund O; Halldner-Henriksson L; Yang J; Eriksson TM; Jacobson MA; Daré E; Fredholm BB
Physiol Behav; 2008 Dec; 95(5):668-76. PubMed ID: 18930070
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands.
Federico S; Spalluto G
Expert Opin Ther Pat; 2012 Apr; 22(4):369-90. PubMed ID: 22435652
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological preconditioning with adenosine A(1) receptor agonist suppresses cellular immune response by an A(2A) receptor dependent mechanism.
Naamani O; Chaimovitz C; Douvdevani A
Int Immunopharmacol; 2014 May; 20(1):205-12. PubMed ID: 24560904
[TBL] [Abstract][Full Text] [Related]
31. [Blocking Adenosine/A2AR Pathway for Cancer Therapy].
Liu J; Shi Y; Liu X; Zhang D; Bai Y; Xu Y; Wang M
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):460-467. PubMed ID: 35899442
[TBL] [Abstract][Full Text] [Related]
32. The A3 adenosine receptor agonist 2-Cl-IB-MECA facilitates epileptiform discharges in the CA3 area of immature rat hippocampal slices.
Laudadio MA; Psarropoulou C
Epilepsy Res; 2004; 59(2-3):83-94. PubMed ID: 15246113
[TBL] [Abstract][Full Text] [Related]
33. Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity.
Li N; Mu L; Wang J; Zhang J; Xie X; Kong Q; Tang W; Yao X; Liu Y; Wang L; Wang G; Wang D; Jin L; Sun B; Li H
Eur J Immunol; 2012 May; 42(5):1140-51. PubMed ID: 22539289
[TBL] [Abstract][Full Text] [Related]
34. Adenosine A(3) receptor-induced proliferation of primary human coronary smooth muscle cells involving the induction of early growth response genes.
Hinze AV; Mayer P; Harst A; von Kügelgen I
J Mol Cell Cardiol; 2012 Nov; 53(5):639-45. PubMed ID: 22906537
[TBL] [Abstract][Full Text] [Related]
35. Oxygenation and A2AR blockade to eliminate hypoxia/HIF-1α-adenosinergic immunosuppressive axis and improve cancer immunotherapy.
Halpin-Veszeleiova K; Hatfield SM
Curr Opin Pharmacol; 2020 Aug; 53():84-90. PubMed ID: 32841869
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Potential of Highly Selective A
Coppi E; Cherchi F; Venturini M; Lucarini E; Corradetti R; Di Cesare Mannelli L; Ghelardini C; Pedata F; Pugliese AM
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335254
[TBL] [Abstract][Full Text] [Related]
37. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection.
Fishman P; Bar-Yehuda S; Barer F; Madi L; Multani AS; Pathak S
Exp Cell Res; 2001 Oct; 269(2):230-6. PubMed ID: 11570815
[TBL] [Abstract][Full Text] [Related]
38. Potentiation of cytotoxicity of paclitaxel in combination with Cl-IB-MECA in human C32 metastatic melanoma cells: A new possible therapeutic strategy for melanoma.
Soares AS; Costa VM; Diniz C; Fresco P
Biomed Pharmacother; 2013 Oct; 67(8):777-89. PubMed ID: 24035253
[TBL] [Abstract][Full Text] [Related]
39. Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: insight into the receptor activation switch.
Dal Ben D; Buccioni M; Lambertucci C; Kachler S; Falgner N; Marucci G; Thomas A; Cristalli G; Volpini R; Klotz KN
Biochem Pharmacol; 2014 Jan; 87(2):321-31. PubMed ID: 24161786
[TBL] [Abstract][Full Text] [Related]
40. Sufficient numbers of anti-tumor T cells is a condition of maximal efficacy of anti-hypoxia-A2-adenosinergic drugs during cancer immunotherapy.
Sitkovsky MV
Curr Opin Pharmacol; 2020 Aug; 53():98-100. PubMed ID: 32861959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
